Zacks Investment Research downgraded shares of Clementia Pharmaceuticals (NASDAQ:CMTA) from a hold rating to a sell rating in a research report report published on Monday.
According to Zacks, “Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. The company’s lead product consists of palovarotene, a novel RAR? agonist, to treat fibrodysplasia ossificans progressiva, multiple osteochondroma and other diseases. Clementia Pharmaceuticals Inc. is based in Montreal, Canada. “
Separately, Wedbush reissued an outperform rating and set a $26.00 price objective on shares of Clementia Pharmaceuticals in a research report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $27.00.
Clementia Pharmaceuticals (NASDAQ CMTA) traded up $0.20 on Monday, reaching $16.73. The company had a trading volume of 19,400 shares, compared to its average volume of 53,067. The firm has a market capitalization of $493.22 and a PE ratio of -3.27. Clementia Pharmaceuticals has a 52-week low of $15.05 and a 52-week high of $20.15.
Clementia Pharmaceuticals (NASDAQ:CMTA) last released its quarterly earnings data on Monday, November 13th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.52). equities analysts anticipate that Clementia Pharmaceuticals will post -7.83 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Birchview Capital LP bought a new position in Clementia Pharmaceuticals during the third quarter valued at about $372,000. Point72 Asset Management L.P. bought a new position in Clementia Pharmaceuticals during the third quarter valued at about $506,000. Sectoral Asset Management Inc bought a new position in Clementia Pharmaceuticals during the third quarter valued at about $512,000. Victory Capital Management Inc. bought a new position in Clementia Pharmaceuticals during the third quarter valued at about $520,000. Finally, Susquehanna International Group LLP bought a new position in Clementia Pharmaceuticals during the third quarter valued at about $729,000. Institutional investors own 68.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2018/01/16/clementia-pharmaceuticals-cmta-rating-lowered-to-sell-at-zacks-investment-research.html.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.